Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
HengRui goes pivotal in KRAS G12D
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
Nuvation reroutes its glioma plan
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Novartis trips over the Hippo
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
